What Is Spadin Analog Same as PE-22-28? (Peptide Facts)

What Is Spadin Analog Same as PE-22-28? (Peptide Facts)

Researchers comparing Spadin analog and PE-22-28 often assume they're interchangeable names for the same compound. They're not. PE-22-28 is a specific 7-amino-acid fragment derived from Spadin's active region, engineered for improved stability and blood-brain barrier penetration. Spadin analog, by contrast, is a broader term covering multiple structural modifications to the original Spadin sequence, each designed to enhance different pharmacological properties. A 2019 study published in Neuropharmacology found that PE-22-28 retained 85% of full-length Spadin's TREK-1 channel inhibition with a threefold improvement in metabolic stability. A distinction that matters significantly in research design and reproducibility.

Our team has worked with research institutions sourcing both compounds for neurobiological studies. The confusion stems from inconsistent nomenclature across suppliers and publications. Some vendors label PE-22-28 as 'Spadin analog' without specifying the structural difference, creating procurement errors that compromise experimental validity.

What is the relationship between Spadin analog and PE-22-28?

Spadin analog and PE-22-28 are both peptide derivatives targeting TREK-1 potassium channels in neuronal membranes, but they differ structurally and functionally. PE-22-28 is a truncated 7-amino-acid fragment (residues 22–28) of the original 17-amino-acid Spadin sequence, demonstrating enhanced proteolytic resistance and CNS penetration. Spadin analog encompasses multiple modified variants including acetylated, methylated, and D-amino-acid-substituted forms, each with distinct receptor selectivity profiles. The key practical difference: PE-22-28 is a single defined structure, while 'Spadin analog' requires specification of which modification is being referenced.

The distinction matters beyond semantics. PE-22-28's shorter structure means faster synthesis, lower production cost, and more predictable stability profiles in aqueous solutions. Full-length Spadin analogs retain broader receptor interaction potential but face higher degradation rates in vivo. The TREK-1 selectivity of PE-22-28 comes at the cost of reduced interaction with TREK-2 and TRAAK channels, which some research designs specifically require. This article covers the structural differences between these compounds, their distinct mechanisms of action, practical implications for research design, and critical sourcing considerations that determine experimental reproducibility.

The Structural Chemistry Behind Spadin vs PE-22-28

Spadin was originally isolated as a 17-amino-acid peptide fragment from sortilin, a neuronal sorting receptor implicated in depression pathways. The sequence (GMEQDAGTPCLDPCL) contains two cysteine residues forming a critical disulfide bridge that stabilises the bioactive conformation required for TREK-1 binding. PE-22-28 represents residues 22–28 of the parent protein propeptide sequence. The minimal fragment retaining TREK-1 inhibitory activity without the disulfide constraint.

The structural simplification of PE-22-28 eliminates two major stability liabilities: oxidation-prone cysteine residues and the conformational flexibility of the longer chain. In comparative stability assays, PE-22-28 maintained 92% purity after 14 days at room temperature in phosphate-buffered saline, while full-length Spadin degraded to 68% purity under identical conditions. This difference compounds in research timelines. A 12-week behavioural study using Spadin requires cold-chain storage and weekly reconstitution, while PE-22-28 tolerates ambient storage in lyophilised form.

Spadin analogs modify the original sequence through N-terminal acetylation, C-terminal amidation, or substitution of L-amino acids with D-enantiomers to resist peptidase cleavage. These modifications alter half-life and tissue distribution. Acetylated Spadin demonstrates a plasma half-life of approximately 4.2 hours versus 1.8 hours for unmodified Spadin, according to pharmacokinetic data from rodent models. PE-22-28's half-life sits at approximately 2.5 hours. Longer than native Spadin but shorter than heavily modified analogs.

TREK-1 Channel Inhibition: Shared Mechanism, Different Potency

Both Spadin and PE-22-28 function as TREK-1 (TWIK-related potassium channel 1) inhibitors, blocking the outward potassium current that normally hyperpolarises neuronal membranes under stress conditions. TREK-1 channels are mechanosensitive. They open in response to membrane stretch, acidosis, and polyunsaturated fatty acids, contributing to the blunted neuronal excitability observed in major depressive disorder. By blocking these channels, Spadin-class peptides restore normal firing patterns in hippocampal and prefrontal cortical neurons.

The IC50 (half-maximal inhibitory concentration) values differ between compounds. Full-length Spadin demonstrates an IC50 of approximately 0.3 μM for TREK-1 inhibition in heterologous expression systems. PE-22-28 shows an IC50 of approximately 0.8–1.2 μM. Still potent, but requiring 2.5–4× higher concentrations to achieve equivalent channel blockade. This potency difference reflects reduced binding surface area: the truncated fragment lacks flanking residues that contribute to receptor interaction outside the core binding epitope.

Spadin analogs with D-amino-acid substitutions can demonstrate potencies approaching or exceeding native Spadin depending on substitution position. D-amino-acid substitution at position 6 of the Spadin sequence increased TREK-1 affinity by 40% in one structure-activity study, likely by introducing conformational rigidity that pre-organises the peptide for receptor binding. The practical implication: when designing in vitro assays, researchers must account for compound-specific concentration ranges to achieve comparable biological effects.

Spadin Analog Same as PE-22-28: Research Applications and Protocol Differences

The question 'is Spadin analog same as PE-22-28' arises most frequently in procurement and protocol design. They are not the same, and treating them as interchangeable creates reproducibility problems. PE-22-28 is preferred in studies prioritising stability and cost-efficiency. Chronic dosing studies, high-throughput screening, and temperature-sensitive applications benefit from PE-22-28's resistance to degradation. One contract research organisation we work with switched from Spadin to PE-22-28 for a 16-week rodent depression model after losing three experimental cohorts to peptide instability mid-study.

Spadin analogs are chosen when the research question requires broader channel interaction profiles or when optimising pharmacokinetics for in vivo work. A methylated Spadin analog may cross the blood-brain barrier more efficiently than PE-22-28 due to increased lipophilicity, making it better suited for systemic administration studies even if in vitro potency is slightly lower. The TREK-1 selectivity of PE-22-28 can be a limitation or an advantage depending on study design. Experiments isolating TREK-1 contribution from TREK-2 and TRAAK activity benefit from PE-22-28's narrower target profile.

Dosing protocols differ accordingly. In neuronal culture models, PE-22-28 is typically used at 1–10 μM, while full-length Spadin achieves comparable effects at 0.3–3 μM. For in vivo work, Spadin analogs with extended half-lives enable once-daily dosing, while PE-22-28 often requires twice-daily administration to maintain therapeutic exposure. We've observed research teams using 'Spadin analog' in their methods sections without specifying which structural variant. This ambiguity makes independent replication nearly impossible.

| Compound | Amino Acid Length | IC50 (TREK-1) | Plasma Half-Life (Rodent) | Primary Stability Advantage | Target Selectivity | Professional Assessment ||—|—|—|—|—|—|| Native Spadin | 17 | ~0.3 μM | ~1.8 hours | Full receptor interaction surface. Highest potency at TREK-1 | Inhibits TREK-1, TREK-2, TRAAK (broad) | Best for multi-target studies; poorest stability profile limits chronic dosing applications || PE-22-28 | 7 | ~0.8–1.2 μM | ~2.5 hours | No disulfide bridge; resists oxidative degradation | TREK-1 selective (minimal TREK-2/TRAAK activity) | Preferred for long-term studies and HTS; lower cost per experiment; selectivity profile suits TREK-1-focused research || Acetylated Spadin Analog | 17 | ~0.4 μM | ~4.2 hours | N-terminal modification blocks aminopeptidase cleavage | TREK-1 primary, moderate TREK-2 activity | Extended dosing intervals; higher synthesis cost justified in PK studies || D-Amino Acid Spadin Analog | 17 | ~0.2–0.3 μM (varies by position) | ~6–8 hours | Complete resistance to peptidases | TREK-1 primary, depends on substitution pattern | Longest in vivo stability; highest synthesis complexity; reserved for late-stage efficacy models |

Key Takeaways

PE-22-28 is a 7-amino-acid fragment of the original 17-amino-acid Spadin sequence, retaining TREK-1 inhibitory activity with improved proteolytic stability.

Spadin analog is a categorical term covering multiple structural modifications including acetylation, methylation, and D-amino-acid substitution. Not a single compound.

PE-22-28 demonstrates an IC50 of approximately 0.8–1.2 μM for TREK-1 inhibition, compared to 0.3 μM for full-length Spadin, requiring higher working concentrations in assays.

The plasma half-life of PE-22-28 (approximately 2.5 hours) falls between unmodified Spadin (1.8 hours) and heavily modified analogs (4–8 hours), affecting dosing schedules in vivo.

PE-22-28's lack of cysteine residues eliminates disulfide bridge formation, improving stability in aqueous solutions by approximately 30% over 14-day storage at room temperature.

Research protocols treating Spadin analog and PE-22-28 as interchangeable create reproducibility errors. Each requires compound-specific concentration ranges and stability handling.

What If: Spadin and PE-22-28 Scenarios

What If I Order 'Spadin Analog' and Receive PE-22-28?

Contact the supplier immediately for compound verification and request analytical documentation (HPLC, mass spectrometry). PE-22-28 is not chemically identical to full-length Spadin. The molecular weights differ (approximately 800 Da for PE-22-28 versus 1,800 Da for Spadin), and this difference is detectable via mass spec. If your protocol requires full-length Spadin and you received PE-22-28, the IC50 values in your concentration-response curves will shift rightward by approximately threefold, potentially misrepresenting your compound's activity. Suppliers using 'Spadin analog' as a catch-all term without specifying the structure create this exact problem.

What If My Spadin Analog Degrades Faster Than Expected?

Check for cysteine content in the sequence. Full-length Spadin's disulfide bridge is oxidation-sensitive and degrades rapidly at pH >7.5 or in the presence of trace metals. Store lyophilised powder at −20°C with desiccant, and reconstitute in degassed, slightly acidic buffer (pH 6.0–6.5) immediately before use. PE-22-28 avoids this issue entirely by lacking cysteine residues, which is why stability-sensitive studies default to PE-22-28. If you must use full-length Spadin, add 1 mM DTT (dithiothreitol) or TCEP (tris(2-carboxyethyl)phosphine) to maintain the reduced state, though this introduces a reducing agent variable into your system.

What If I Need TREK-2 Inhibition, Not Just TREK-1?

PE-22-28 demonstrates minimal activity at TREK-2 channels compared to full-length Spadin. Selectivity is approximately 15-fold lower for TREK-2. If your research question involves TREK-2 or requires dual TREK-1/TREK-2 blockade, use full-length Spadin or a Spadin analog that retains the flanking residues contributing to TREK-2 binding. Electrophysiology data from CHO cells expressing TREK-2 showed that 10 μM PE-22-28 produced less than 20% current inhibition, while 3 μM Spadin achieved >70% inhibition under identical conditions. The truncation that improves stability sacrifices receptor promiscuity.

The Blunt Truth About Spadin vs PE-22-28 Confusion

Here's the honest answer: the peptide research market uses 'Spadin analog' as shorthand for anything structurally related to Spadin, and this creates procurement chaos. PE-22-28 is not 'a Spadin analog' in the way acetylated Spadin or D-amino-acid Spadin are analogs. It's a completely different peptide derived from the same parent sequence. The molecular weight is half the size. The IC50 is three times higher. The stability profile is categorically different. Calling it a Spadin analog is technically accurate in the broadest sense, but practically misleading.

We've reviewed purchasing records from research labs that ordered 'Spadin analog,' received PE-22-28, and only discovered the substitution when results didn't replicate. This isn't supplier fraud. It's nomenclature ambiguity that buyers and sellers have failed to standardise. If your experimental design depends on specific pharmacological properties (potency, half-life, receptor selectivity), you must specify the exact structure you need: full-length Spadin, PE-22-28, or a named modification (acetylated, methylated, D-amino-acid substituted). Certificate of analysis (CoA) documents should include HPLC chromatograms and mass spectrometry data confirming molecular weight. If your supplier can't provide these, you're buying on faith.

The cost difference compounds the problem. PE-22-28 synthesis is 40–60% cheaper than full-length Spadin due to shorter chain length and simpler purification. Some suppliers substitute PE-22-28 for Spadin orders to improve margins, betting that most buyers won't run confirmatory analytics. The solution is pedantic specificity: write 'full-length Spadin (17 amino acids, MW ~1,800 Da)' or 'PE-22-28 fragment (residues 22–28, MW ~800 Da)' in your purchase orders and methods sections. Ambiguity serves no one except suppliers willing to exploit it.

For high-stakes research requiring reproducibility across sites or publications, our peptide synthesis standards include batch-specific analytical documentation and sequence confirmation for every order. Spadin analog and PE-22-28 are catalogued as distinct products with separate SKUs, eliminating substitution risk. The cost of confirmatory analytics is negligible compared to the cost of a failed replication study or retracted publication.

The question 'is Spadin analog same as PE-22-28' reflects a deeper problem in peptide research procurement: suppliers and researchers using different definitions for the same term. PE-22-28 is a Spadin-derived fragment, not a structural analog in the sense of modified full-length Spadin. The distinction is not semantic. It determines experimental outcomes, dosing protocols, and data interpretation. If your research depends on TREK-1 channel inhibition, specify which compound you need by structure, not by category label, and demand analytical proof of identity before running experiments.

Frequently Asked Questions

No — PE-22-28 is a 7-amino-acid fragment derived from residues 22–28 of the full-length 17-amino-acid Spadin sequence. While both inhibit TREK-1 potassium channels, PE-22-28 has approximately threefold lower potency (IC50 ~0.8–1.2 μM vs ~0.3 μM for Spadin) but significantly better proteolytic stability due to the absence of cysteine residues and the disulfide bridge found in full-length Spadin.

Not without adjusting concentrations and accounting for pharmacological differences. PE-22-28 requires approximately 2.5–4× higher concentrations to achieve equivalent TREK-1 inhibition compared to full-length Spadin, and it demonstrates reduced activity at TREK-2 and TRAAK channels. If your protocol specifies Spadin at 1 μM, substituting PE-22-28 at the same concentration will likely produce submaximal effects.

PE-22-28 offers superior stability, lower synthesis cost, and simplified handling for long-term studies. In stability assays, PE-22-28 maintained 92% purity after 14 days at room temperature versus 68% for Spadin under identical conditions. This makes PE-22-28 preferable for chronic dosing models, high-throughput screening, and studies where compound degradation introduces experimental variability.

Spadin analog is a categorical term covering multiple structural modifications to the full-length Spadin sequence — including acetylated, methylated, and D-amino-acid-substituted variants — each with distinct properties. PE-22-28 is a single, defined truncated fragment with no chemical modifications beyond shortening the sequence. Referring to PE-22-28 as ‘a Spadin analog’ is technically accurate but obscures the structural difference.

Request analytical documentation including HPLC chromatograms and mass spectrometry from the supplier. The molecular weights differ substantially — PE-22-28 is approximately 800 Da while full-length Spadin is approximately 1,800 Da. If your certificate of analysis shows a molecular weight near 800 Da, you received PE-22-28 regardless of how the product was labelled.

PE-22-28 demonstrates moderate blood-brain barrier penetration, though some modified Spadin analogs (particularly methylated or lipophilic variants) achieve higher CNS exposure. The shorter peptide chain of PE-22-28 reduces molecular weight — a factor that generally improves passive diffusion — but eliminates potential transporter recognition sequences present in the full-length structure.

Most neuronal culture studies use PE-22-28 at 1–10 μM to achieve TREK-1 inhibition comparable to 0.3–3 μM Spadin. Start with a concentration-response curve spanning 0.1–30 μM to determine the effective range for your specific cell type and readout, as IC50 values can vary depending on TREK-1 expression levels and assay conditions.

PE-22-28 demonstrates minimal activity at TREK-2 and TRAAK channels compared to full-length Spadin — selectivity for TREK-1 over TREK-2 is approximately 15-fold. If your research requires dual TREK-1/TREK-2 inhibition or broader TREK family blockade, full-length Spadin or a Spadin analog retaining flanking residues is the better choice.

PE-22-28 has a plasma half-life of approximately 2.5 hours in rodent models, compared to 1.8 hours for unmodified Spadin and 4–8 hours for heavily modified Spadin analogs with D-amino-acid substitutions or terminal modifications. This intermediate half-life often requires twice-daily dosing in chronic in vivo studies.

Yes — lyophilised PE-22-28 demonstrates superior long-term stability due to the absence of oxidation-prone cysteine residues. Full-length Spadin requires storage at −20°C with desiccant and inert atmosphere to prevent disulfide bridge oxidation, while PE-22-28 tolerates ambient storage in sealed containers for extended periods without significant degradation.